The relationship between Fusobacterium species and other flora in mixed infection

References

1. Abe P. M., Lennard E. S., Holland J. W. 1976; Fusobacterium necrophorum infection in mice as a model for the study of liver abscess formation and induction of immunity. Infection and Immunity 13:1473–1478
   [Google Scholar]
2. Altemeier W. A. 1942; The pathogenicity of the bacteria of appendicitis peritonitis: an experimental study. Surgery 11:374–384
   [Google Scholar]
3. Brook I. 1983 Anaerobic infections in childhood G. K. Hall, Medical Publisher; Boston, MA:
   [Google Scholar]
4. Brook I., Gillmore J. D., Coolbaugh J. C., Walker R. I. 1983; Pathogenicity of encapsulated Bacteroides melaninogenicus group, Bacteroides oralis, and Bacteroides ruminicola subspecies brevis in abscesses in mice. Journal of Infection 7:218–226
   [Google Scholar]
5. Brook I., Walker R. I. 1983; Infectivity of organisms recovered from polymicrobial abscesses. Infection and Immunity 42:986–989
   [Google Scholar]
6. Brook I., Walker R. I. 1984; Pathogenicity of anaerobic Gram positive cocci. Infection and Immunity 45:320–324
   [Google Scholar]
7. Conlon P. J., Hepper K. P., Teresa G. W. 1977; Evaluation of experimentally induced Fusobacterium necrophorum infections in mice. Infection and Immunity 15:510–517
   [Google Scholar]
8. Hill G. B., Osterhout S., Pratt P. C. 1974; Liver abscess production by non-spore-forming anaerobic bacteria in a mouse model. Infection and Immunity 9:599–603
   [Google Scholar]
9. Hite K. E., Locke M., Hesseltine H. C. 1949; Synergism in experimental infections with non-sporulating anaerobic bacteria. Journal of Infectious Diseases 84:1–9
   [Google Scholar]
10. Kasper D. L. 1976; The polysaccharide capsule of Bacteroides fragilis subspecies fragilis: Immunochemical and morphologic definition. Journal of Infectious Diseases 133:79–89
    [Google Scholar]
11. Lennette E. H., Balows A., Hausler W. J., Truant J. P. 1980 Manual of clinical microbiology, 3rd edn. American Society for Microbiology; Washington, D.C.:
    [Google Scholar]
12. Lev M., Keudell K. C., Milford A. F. 1971; Succinate as a growth factor for Bacteroides melaninogenicus. Journal of Bacteriology 108:175–178
    [Google Scholar]
13. Lummis W. L., Davidson G. M. R., Wilson J. W. 1978 Clindamycin. In Reeves D. S. et al. (eds) Laboratory methods in antimicrobial chemotherapy Churchill Livingstone; Edinburgh: p 216
    [Google Scholar]
14. MacDonald J. B., Sutton R. M., Knoll M. L., Madlener E. M., Grainger R. M. 1956; The pathogenic components of an experimental fusospirochetal infection. Journal Infectious Diseases 98:15–20
    [Google Scholar]
15. Mergenhagen S. E., Thonard J. C., Scherp H. W. 1958; Studies on synergistic infections. 1. Experimental infections with anaerobic streptococci. Journal of Infec tious Diseases 103:33–44
    [Google Scholar]
16. Okuda K., Takazoe I. 1973; Antiphagocytic effects of the capsular structure of a pathogenic strain of Bacteroides melaninoge-nicus. Bulletin of the Tokyo Dental College 14:99–104
    [Google Scholar]
17. Onderdonk A. B., Kasper D. L., Cisneros R. L., Bartlett J. G. 1977; The capsular polysaccharide of Bacteroides fragilis as a virulence factor: Comparison of the pathogenic potential of encapsulated and unencapsulated strains. Journal of Infectious Diseases 136:82–89
    [Google Scholar]
18. Simon G. L., Klempner M. S., Kasper D. L., Gorbach S. L. 1982; Alterations in opsonophagocytic killing by neutrophils of Bacteroides fragilis associated with animal and laboratory passage: effect of capsular polysaccharide. Journal of Infectious Diseases 145:72–77
    [Google Scholar]
19. Sutter V. L., Citron D. M., Finegold S. M. 1980 Wadsworth Anaerobic Bacteriology Manual, 3rd edn. C.V. Mosby; St Louis:
    [Google Scholar]
20. Thornsbury C., Svenson J. M. 1978; Antimicrobial susceptibility testing of anaerobes. Laboratory Medicine 9:1043–48
    [Google Scholar]
21. Wheeler L. A., DeMeo M., Halula M., George L., Heseltine P. 1978; Use of high pressure liquid chromatography to determine plasma levels of metronidazole and metabolites after intravenous administration. Antimicrobial Agents and Chemotherapy 13:205–209
    [Google Scholar]